NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee A) meeting minutes

 **Minutes:** Confirmed

**Date and time:** Tuesday 5 January 2021, 9:30am – 17:10pm

**Location:** via Zoom

## Committee members present:

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Mr Richard Ballerand Present for all items
4. Dr Andrew Champion Present for all items
5. Dr Justin Daniels Present for all items
6. Dr Steve Edwards Present for items 6 to 8
7. Dr Rita Faria Present for all items
8. Rebecca Harmston (TAC D) Present for all items
9. Professor Khalida Ismail Present for all item
10. Dr Megan John (TAC B) Present for all items
11. Professor G.J. Melendez-Torres Present for items 1 to 5 and 7 to 8
12. Ms Stella O’Brien (TAC C) Present for all items
13. Mrs Becky Pennington Present for all items
14. Ms Pamela Rees Present for all items
15. Dr Mohit Sharma Present for all items
16. Dr Stephen Sharp Present for items 1 to 5
17. Dr Alice Turner Present for items 1 to 7.1
18. Dr Roger Whittaker Present for all items

## NICE staff present:

Henry Edwards, Associate Director Present for items 1 to 5

Janet Robertson, Associate Director Present for all items

Jeremy Powell, Project Manager Present for items 1 to 4 and 6

Thomas Feist, Project Manager Present for items 5, 7 and 8

Carl Prescott, Technical Advisor Present for items 1 to 5

Emily Eaton-Turner, Technical Advisor Present for items 1 to 5

Ellie Donegan, Technical Advisor Present for item 6

Joanna Richardson, Technical Advisor Present for items 7 and 8

Sharlene Ting, Technical Analyst Present for items 1 to 5

Sue Harnan, Technical Lead, (contractor) Present for items 1 to 5

Farhaan Jamadar, Technical Analyst Present for item 6

Marcela Haasova, Technical Analyst Present for items 7 and 8

Heidi Livingstone, Public Involvement Advisor Present for items 7 and 8

Mira Patel, Coordinator Present for all items

Rosalee Mason, Coordinator Present for items 1 to 4 and 6

Catherine Pank, Coordinator Present for items 5, 7 and 8

Sophie McHugh, Administrator Present for items 1 to 4 and 6

Marcia Miller, Administrator Present for items 5, 7 and 8

## External group representatives present:

Rebecca Boffa, Senior HTA Analyst, BMJ TAG Present for items 1 to 4.2

Gemma Marceniuk, Health Economist, BMJ TAG Present for items 1 to 4.2

Mariana Bacelar, Principal Health Economist, BMJ TAG Present for item 5.1

Charlotta Karner, HTA Analysis Manager, BMJ TAG Present for item 5.1

G.J. Melendez-Torres, Director, PenTAG Present for item 6.1

Ash Bullement, Lead Economist, PenTAG Present for item 6.1

Tracey Jhita, Health Economics Manager, BMJ TAG  Present for item 7.1

Vicky Wakefield, Principal HTA Analyst, BMJ TAG Present for item 7.1

## Professional experts present:

Professor Peter Clark, CDF Clinical Lead, NHSE&I Present for all items

Dr Duncan Wheatley, Consultant Oncologist Present for items 1 to 4.1

 Royal Cornwall Hospital NHS Trust

Holly Heath, Policy Manager, Breast Cancer Now Present for items 1 to 5.1

Dr Mark Verrill, Consultant Medical Oncologist Present for item 5.1

 Northern Centre for Cancer Care

Professor Ruth Plummer, Clinical Professor of Experimental Present for item 7.1

 Cancer Medicine, Honorary Consultant Medical

 Oncologist Newcastle University and Newcastle

 Hospitals NHS Trust

## Observers present:

Adam Storrow, Business Analyst Present for items 1 to 7.1

Ella Livingstone, Technical Adviser Present for all items

Ria Skelton, Senior Medical Editor Present for items 1 to 4

Ann Greenwood, Senior Medical Editor Present for item 5

Sarah Bromley, Senior Medical Editor Present for item 6

Olivia Havercroft, Senior Medical Editor Present for items 7 and 8

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Mr Peter Baker, Mr Min Ven Teo, Professor John McMurray, Dr Minal Bakhai, Dr Sumithra Maheswaran and Dr Sarah Parry.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. No minutes were confirmed.

### Appraisal of Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer [ID3755] (CDF Review of TA593)

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Novartis.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Steve Edwards, Committee Member, declared prior to the meeting a non-financial professional & personal interest as BMJ Group is the ERG for this topic. It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Dr Duncan Wheatley, clinical expert, declared a direct financial interest as he had previously been on advisory boards for Novartis. It was agreed that this declaration would not prevent Dr Wheatley from providing expert advice to the committee.
* Holly Heath, patient expert, declared an indirect interest as Breast Cancer Now has received funding from Novartis. It was agreed that this declaration would not prevent Holly from providing expert advice to the committee.

No further conflicts of interest were declared for this item.

* 1. Part 2a – Closed session (members of the public, company representatives and professional experts were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727] (CDF Review of TA579)

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Eli Lilly.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Steve Edwards, Committee Member, declared prior to the meeting a non-financial professional & personal interest as BMJ-TAG is the ERG for this topic. It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Dr Mark Verrill, clinical expert, declared a direct financial interest as he had previously received honoraria from Eli Lilly for lecturing, advisory boards and consultancy. It was agreed that this declaration would not prevent Dr Verrill from providing expert advice to the committee.
* Holly Heath, patient expert, declared an indirect interest as Breast Cancer Now has previously received funding from Eli Lilly. The funding is not related to policy and campaign work. It was agreed that this declaration would not prevent Holly from providing expert advice to the committee.

 No further conflicts of interest were declared for this item.

* 1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Bristol-Myers Squibb.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
		3. No conflicts of interest were declared for this technology
	2. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease [ID1681] (Review of TA558)

* 1. Part 1 – Open session
		1. The vice-chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Bristol-Myers Squibb.
		2. The vice-chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Steve Edwards, Committee Member, declared prior to the meeting a non-financial professional & personal interest as BMJ-TAG is the ERG for this topic. It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Professor Ruth Plummer, clinical expert, declared direct financial interests as she had received honoraria recently from BMS for chairing an educational meeting. Professor Plummer also declared that in the last two years, she had received honoraria from BMS for advisory boards, delivering and/or chairing educational meetings and supporting attendance at conferences. She has also done paid work for several other pharmaceutical companies not related to this appraisal. It was agreed that this declaration would not prevent Professor Plummer from providing expert advice to the committee.

 No further conflicts of interest were declared for this item.

* 1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee A) will be held on Tuesday 2 February 2021 and will start promptly at 9:30am.